Structure Therapeutics (GPCR) Projected to Announce Earnings on Thursday

Key Points

• Structure Therapeutics is expected to report Q3 2026 results before the market opens on November 5. Analysts forecast a loss of $0.325 per share and revenue of $50 million; the earnings call is scheduled for November 6 at 4:00 p.m. ET.
• The company reported a larger-than-expected Q2 loss of $0.49 per share, compared with the consensus estimate of $0.39, and analysts project full-year and next-year losses of $1.87 and $2.09 per share, respectively.
• GPCR shares opened at $21.48, near their 12-month low of $20.50 and well below the $94.90 high. Despite recent downgrades, analysts maintain a consensus “Moderate Buy” rating with a $110.91 target price, while the company advances its oral GLP-1 candidate GSBR-1290.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) is expected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Structure Therapeutics to post earnings of ($0.3250) per share and revenue of $50.00 million for the quarter. Individuals may visit the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10). On average, analysts expect Structure Therapeutics to post ($1.87) EPS for the current fiscal year and ($2.09) EPS for the next fiscal year.

Structure Therapeutics Stock Down 0.3%

Shares of GPCR opened at $21.48 on Thursday. Structure Therapeutics has a 12-month low of $20.50 and a 12-month high of $94.90. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -21.48 and a beta of -1.30. The stock's 50-day moving average price is $34.65 and its 200 day moving average price is $49.91.

Analyst Upgrades and Downgrades

GPCR has been the subject of a number of research reports. Weiss Ratings downgraded Structure Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, October 23rd. HC Wainwright restated a "buy" rating on shares of Structure Therapeutics in a research report on Wednesday, September 9th. Citigroup restated a "market outperform" rating on shares of Structure Therapeutics in a research report on Friday, August 7th. Wall Street Zen lowered Structure Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, October 3rd. Finally, Canaccord Genuity Group set a $111.00 target price on Structure Therapeutics in a research report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $110.91.

Structure Therapeutics Company Profile

Structure Therapeutics NASDAQ: GPCR is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic diseases. The company uses structure-based drug discovery and focuses on G protein-coupled receptors (GPCRs), a broad class of drug targets involved in metabolic and cardiovascular processes.

Its lead product candidate is GSBR-1290, an investigational oral GLP-1 receptor agonist being developed for obesity and type 2 diabetes. Structure Therapeutics is also advancing additional discovery and preclinical programs intended to address metabolic and related chronic diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.